Results 261 to 270 of about 10,662,454 (348)

Leveraging Macrophage Metabolic Reprogramming for Enhanced Anti‐Tumor Immunity

open access: yesAdvanced Science, EarlyView.
Tumor‐associated macrophages (TAMs) are key regulators of the tumor microenvironment (TME), with their metabolic states playing a critical role in tumor progression or regression. This review summarizes current understanding of TAM metabolic plasticity alongside cutting‐edge bioengineering innovations, outlining a roadmap for transforming the ...
Zhiyun Liu   +8 more
wiley   +1 more source

CD28‐Targeted Enzyme‐Responsive Conformation‐Switching Peptide Self‐Assembly for Selective T‐Cell Acute Lymphoblastic Leukemia (T‐ALL) Therapy

open access: yesAdvanced Science, EarlyView.
We developed the enzyme‐responsive peptide SAp‐CD28 to selectively target CD28‐overexpressing T‐ALL cells. Following phosphatase‐mediated activation, SAp‐CD28 undergoes conformational switching and nanooligomerization, resulting in the disruption of CD28 downstream signaling.
Jun Li   +10 more
wiley   +1 more source

Novel Vascular‐Adaptive Liquid Metal Microspheres Enable Visualized Arterial Embolization Therapy

open access: yesAdvanced Science, EarlyView.
We present drug‐loaded liquid metal microspheres (X‐MEN) as a novel agent for image‐guided arterial embolization. With inherent radiopacity and superior deformability, X‐MEN enables real‐time monitoring and conforms tightly to irregular vessels. This approach ensures precise, long‐lasting embolization without recanalization, addressing critical ...
Chenyu Shen   +14 more
wiley   +1 more source

IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial

open access: yesBlood Cancer Journal
Sheng-Li Xue   +32 more
doaj   +1 more source

Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

open access: yesAdvanced Science, EarlyView.
The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li   +10 more
wiley   +1 more source

Bench‐to‐Bedside Translation of Self‐Healing Colloidal Hydrogels as Next Generation Design of Flowable Hemostatic Matrix: From Preclinical Evaluation to Human Clinical Trials

open access: yesAdvanced Science, EarlyView.
ABSTRACT Self‐healing materials represent a paradigm shift in designing functional biomedical devices for drug delivery, tissue regeneration, and 3D bioprinting. However, their clinical translation remains limited by challenges such as insufficient mechanical strength, potential cytotoxicity from chemical modifications, and complex activation ...
Ganjun Feng   +15 more
wiley   +1 more source

Tumor‐Derived Exosomes Deliver Membrane‐Bound Fgl2 to Activate FcγRIIB‐Mediated Immunosuppression in Myeloid‐Derived Suppressor Cells

open access: yesAdvanced Science, EarlyView.
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin   +12 more
wiley   +1 more source

Diagnostic value of procalcitonin in infections in patients with malignant hematologic diseases. [PDF]

open access: yesZhong Nan Da Xue Xue Bao Yi Xue Ban
Liu M   +7 more
europepmc   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy